Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 3/20 | 0.61 |
| ▸ | UGCG | Q16739 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028418 | 0.83 | CHRNA7 (0.52) | CHRNA3HPGDHSD11B1CHRNA7HTR3A | |
| SCHEMBL4025885 | 0.81 | CHRNA7 (0.51) | CHRNA3HSD11B1CHRNA7TSHR | |
| SCHEMBL4031149 | 0.78 | CHRNA7 (0.54) | CHRNA3HSD11B1CHRNA7HTR3A | |
| SCHEMBL4028207 | 0.78 | CHRNA3 (0.64) | CHRNA3HPGDCHRNA7TSHRHTR3A | |
| SCHEMBL4028569 | 0.77 | CHRNA7 (0.62) | CHRNA3HPGDHSD11B1CHRNA7HTR3A | |
| SCHEMBL4031884 | 0.77 | CHRNA7 (0.52) | CHRNA3CHRNA7HTR3A | |
| SCHEMBL4030570 | 0.76 | CHRNA7 (0.60) | CHRNA3CHRNA7HTR3A | |
| SCHEMBL7553764 | 0.76 | CHRNA3 (1.00) | CHRNA3CHRNA7HTR3A | |
| SCHEMBL4029985 | 0.75 | CHRNA7 (0.51) | CHRNA3CHRNA7HTR3A | |
| SCHEMBL4027734 | 0.75 | HSD11B1 (0.53) | HPGDHSD11B1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | claimed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | CHRNA3 13/4885UGCG 3606/4885HPGD 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.